The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

The fast-growing nootropics market is set to reach $24.63 billion by 2030. These brain-boosting supplements are becoming more ...

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...

Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...

Share on Pinterest The FDA has approved ... receptors in the brain and other areas of the central nervous system are mainly responsible for cognitive skills learning and memory.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

The decision builds on previous FDA approval for the drug’s treatment when combined ... is its ability to travel through a different brain pathway affecting the neurotransmitter, glutamate.

21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone ... Spravato targets glutamate in the brain, which is the most abundant excitatory neurotransmitter.

was just approved as a stand-alone therapy by the Food and Drug Administration. "Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral ...

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...